Waleed serves as Mubadala’s Deputy Group Chief Executive Officer, and has strategic oversight of the company’s broad investment portfolio and special projects at the group level. He is also a member of the investment committee, which is mandated to develop Mubadala’s investment policies, establish investment guidelines, and review proposed projects and investments to ensure they are in line with business objectives.
Waleed is also the Chairman to Mubadala's new investment and business planning committee, which approves deals within a certain financial threshold in addition to the l responsibility of annual and multi-year business planning. Furthermore, Waleed has oversight of the Real Estate & Infrastructure and Disruptive platforms.
Prior to joining Mubadala, Waleed worked with the UAE Offsets Program Bureau as a Senior Project Manager. Past roles also include working with McKinsey & Company as a consultant.
Waleed holds a Master’s Degree in Public Policy from Harvard University, USA, and a Bachelor of Science Degree in Foreign Service from Georgetown University, USA.
Chairman of Cleveland Clinic Abu Dhabi, Mubadala Capital, Waha Capital, Global Institute for Disease Elimination (GLIDE), the US-UAE Business Council and Mubadala Health.
In addition, Waleed is a member of the Board of Trustees of Cleveland Clinic in the United States. He is also a board member of Aldar, Abu Dhabi Global Market, Noon.com, First Abu Dhabi Bank (FAB), Hub71, Ellipses Pharma Limited, and Investcorp.
Musabbeh is the Chief Executive Officer of Mubadala’s UAE Investments platform. The platform contributes to the acceleration of the UAE’s economic transformation, and investing in national world class champions, fostering vibrant industrial and commercial clusters, and partnering with world-class global entities.
Prior to his current role, Musabbeh was responsible for the company’s substantial international energy portfolio as CEO of the Petroleum & Petrochemicals platform from 2017 to 2020. As CEO, Musabbeh oversaw an integrated energy portfolio of investments valued in excess of $40 billion USD with over 10 asset companies operating along the value chain.
He also served the Group as CEO of Mubadala Petroleum, Mubadala’s wholly owned exploration and Production Company, from 2014 to 2017. During his tenure, he successfully led the company through a challenging period of declining commodity prices, locking in significant cost efficiencies and operational improvements whilst high grading the portfolio to focus on value-adding assets and maintaining an exemplary health and safety record. He joined Mubadala Petroleum in 2013 as Chief Growth Officer, responsible for new business development, mergers & acquisitions and exploration.
Musabbeh began his career at the Abu Dhabi National Oil Company (ADNOC) where he spent 16 years during which he held a series of increasingly senior technical and managerial roles, rising to lead ADNOC’s Exploration Division. In 2005, he had a cross posting with Shell in the Netherlands where he joined as a Geophysicist for a year.
Musabbeh holds a Bachelor of Science degree in Geophysical Engineering from Colorado School of Mines and a Master of Sciences in Petroleum Geoscience from Imperial College, London.
Chairman of Mubadala Petroleum & Yahsat, He is also the Vice Chairman of Borealis, Masdar, Cleveland Clinic Abu Dhabi & Mubadala Health.
He is also board member of Dolphin Energy, Cespa, Nova Chemicals, and Emirates Global Aluminium.
As Mubadala’s Chief Financial Officer, Carlos is responsible for managing the organization’s Business Finance including Treasury and Investor Relations, Financial Planning and Business Performance, and Financial Governance and Reporting.
He is a member of the Board of Directors of several Mubadala Group Companies and other operational businesses. He currently serves as the Chairman of the Board of Directors of Mubadala Infrastructure Partners Ltd, and is also a board member of Cleveland Clinic Abu Dhabi LLC, Global Foundries, Waha Capital, and Abu Dhabi Commercial Bank PJSC.
Before joining Mubadala, Carlos worked with UAE Offset Program Bureau where he led a wide range of initiatives including privatization, utilities and financial services.
Carlos holds a bachelor of Science in Electrical Engineering from American University of Beirut, Lebanon, and a Master of Business Administration from INSEAD in Fontainebleau, France.
Chairman of Mubadala Infrastructure Partners Ltd.
Board Member of Cleveland Clinic Abu Dhabi.
M Ahmed serves as Mubadala’s Chief Strategy & Risk Officer, where he is responsible for the company’s Corporate Strategy, ESG, and Enterprise Risk Management framework.
Before his appointment as CSRO, Ahmed was the CEO, Energy at Mubadala Development Company where he oversaw the company’s energy assets in addition to being a member of the Investment Committee.
Ahmed was also the Director General of the Abu Dhabi Technology Development Committee where his main responsibility was to support the development of Science, Technology and Innovation in Abu Dhabi, through various strategic initiatives as well as through the effective coordination between various government stakeholders.
Prior to his appointment to the Abu Dhabi Technology Development Committee, Ahmed was the CEO & Managing Director of the Abu Dhabi Ports Company, where he played an instrumental role in the development of Khalifa Port.
Ahmed has also served as the Deputy Director of the Infrastructure and Services unit at Mubadala Development Company, where he led a number of major projects and initiatives in the infrastructure and services sectors.
Ahmed’s diverse professional experience includes several leadership positions as well as board positions on various companies. Ahmed holds a Bachelor’s degree in Economics and Political Science from Boston University.
Board Member of Masdar, Cleveland Clinic Abu Dhabi, Mubadala Health, Abu Dhabi Commercial Bank, and Global Foundries.
Dr Maha Barakat is the Director General of the Frontline Heroes Office and a Senior Advisor at Mubadala.
In addition to being a Board member of Mubadala Health, she is the Board Chair of the RBM (roll back malaria) Partnership to End Malaria, and Board member of the Global Institute for Disease Elimination (GLIDE), the Cleveland Clinic Abu Dhabi, the Abu Dhabi Quality Conformity Council, and the Family Development Foundation.
She was previously the Director General of the Health Authority Abu Dhabi from 2013-2018. Prior to this, she co-founded the Imperial College London Diabetes Centre in Abu Dhabi, and was its Medical and Research Director. She is committed to supporting medical research, education and quality improvement in healthcare.
Chairman of the RBM Partnership to End Malaria.
Board Member of Cleveland Clinic Abu Dhabi, Mubadala Health, the Family Development Foundation, and GLIDE.
Hasan Jasem Al Nowais is the Chief Executive Officer (CEO) of Mubadala Health, an integrated healthcare network established by Mubadala Investment Company to drive the sustainable development and growth of the healthcare sector in the UAE and beyond.
In his current role, Hasan leads the operations and performance of the healthcare assets within the Mubadala Health’s portfolio, which includes Cleveland Clinic Abu Dhabi, Healthpoint Hospital, Imperial College London Diabetes Center, Amana Healthcare, National Reference Laboratory, Capital Health Screening Centre, and Abu Dhabi Telemedicine Centre.
Prior to this role, Hasan was the Chief Administrative Officer of Cleveland Clinic Abu Dhabi, where he led the operation of various strategic functions at the hospital. In this capacity, Hasan directed key projects and initiatives, such as the outpatient retail optimization, the delivery of patient experience, the facilitated access for international VIP’s and royal patients, the success of transplant services, and the business intelligence and continuous improvement process.
Hasan joined Mubadala in 2007, and throughout the past 14 years, he has been charged with overseeing international hospitality projects across the United States, the Middle East and other parts of Asia with leading brands such as Viceroy, Four Seasons, and Rosewood.
Alongside his strategic and operational roles at Mubadala Investment Company, Hasan is the Chairman of the Rosewood Abu Dhabi and the Four Seasons Hotel Abu Dhabi, and a board member of the Viceroy Hotel Group.
Prior to joining Mubadala, Hasan worked at various leading international and national entities to include the private department of H.H. Sheikh Zayed bin Sultan Al Nahyan, Ernst &Young, as well as within his family business, the Rotana Hotel Group.
Hasan is a graduate in finance from the American University, Washington DC. He also holds real estate and hospitality investment certification from Cornell University, and leadership in healthcare certification from Harvard Medical School.
Member of the Board of Directors of Cleveland Clinic Abu Dhabi.
Ameena Thabet is currently the Executive Director of Human Capital & Emiratization at Mubadala, and a member of the Management Committee. She is responsible for developing and leading the organization’s people strategy, as well as implementing the frameworks for acquiring, developing, rewarding and retaining talent.
Ameena helps shape Mubadala’s high-performance culture that promotes diversity and inclusion, serving as a steward of creating an engaged and valued workforce. This includes determining best practices to meet the Mubadala’s rapidly changing talent needs, mobilizing the processes and technologies that enhance a variety of human resources capacities such as learning and development, employee experience, talent assessment, rewards and compensation, talent pipeline and succession planning.
Ameena has nearly twenty years of experience across the private and public sectors, both globally and regionally. With her deep understanding of human capital needs and extensive knowledge of process design and application, her contributions have been invaluable in aligning people, culture and business priorities to provide a thriving workplace for employees.
She serves on the Cleveland Clinic Abu Dhabi Board and also spearheads a number of human capital committees within the Mubadala Group.
Ameena holds a Masters of Human Resources Management from Abu Dhabi University.
Toby Cosgrove, MD, is former CEO and current Executive Advisor of Cleveland Clinic. He is Strategic Advisor to Care Centrix, Senior Advisor of Innova Health Partners, and sits on the boards of American Well, and Hims & Hers. As an expert on health issues, he is a frequent commentator in national and international media.
As CEO and President of Cleveland Clinic from 2004 through 2017, he led the $8 billion organization to new heights of achievement and efficiency, seeing it ranked the #2 hospital in America (U.S. News). In his role as Executive Advisor, he is working with Cleveland Clinic leadership on strategies for national and international growth.
Dr. Cosgrove graduated from Williams College and the University of Virginia School of Medicine. He trained at Massachusetts General Hospital and Brook General Hospital in London. In 1967, he was a surgeon in the U.S. Air Force, earning a Bronze Star.
Dr. Cosgrove joined Cleveland Clinic in 1975, and chaired the Department of Thoracic and Cardiovascular surgery from 1989 to 2004. He performed over 22,000 operations and earned an international reputation in valve repair. He holds 30 patents for medical innovations. As CEO from 2004 to 2017, he reorganized services, improved outcomes and patient experience, and strengthened the organization’s finances.
He is a member of the National Academy of Medicine, and a Fellow of the National Academy of Inventors. In 2016, he was a Fortune Businessperson of the Year (No. 14). Three successive presidents of the United States have consulted him on healthcare issues.
Member of the Board of Directors of Cleveland Clinic Abu Dhabi, American Well, and Hims and Hers
Sir Robert recently retired after 16 years as Chief Executive of University College Hospitals (UCLH), one of the largest NHS trusts in the UK.
As Chief Executive, Sir Robert oversaw six central London hospitals and an organisation with an annual turnover of around £1bn and 8,180 staff. Each year, its hospitals deliver more than 500,000 outpatient appointments and admit more than 100,000 patients.
Under Sir Robert’s leadership, UCLH was frequently rated the top performing NHS trust. He leaves an important legacy and a wide-ranging portfolio of initiatives which has bolstered UCLH’s position as a global leader in healthcare and research.
A highpoint in Sir Robert’s career was overseeing 5 phases of development of University College Hospital over nearly two decades. Recent developments included the UK’s first ambulatory cancer centre, a new ENT and Dental Hospital and the National Proton Beam Centre. The latter is part of a £250 million government investment and will deliver pioneering treatment to patients who would otherwise have to travel abroad.
Sir Robert has chaired several national policy development groups including ‘The Future of NHS Leadership’. For the last 5 years he has been the UK Governments National Advisor on NHS Property and Estates which has led to the NHS plan to develop 40 new hospitals with an estimated capital investment of £40bn. Another highlight was chairing the London Chief Executives group and the Shelford Group.
Since retiring, Sir Robert has been using his industry experience to shape healthcare trusts around the world. Recentroles include: Board Director of the Cleveland Clinic Abu Dhabi, Board Director of Everlight Radiology in Australia, Chairman of the UK Advisory Committee to Allscripts in the USA, Chairman of VideoDoc and Chairman of JCM (UK).
Chairman of the UK Advisory Committee to Allscripts USA, VideoDoc, JCM UK.
Director, Everlight Radiology in Australia.
A pioneer in the innovative financing movement for development, Philippe Douste-Blazy is currently the Chair of UNITLIFE, a United Nations Fund dedicated to the fight against chronic malnutrition in the world.
Douste-Blazy is widely regarded as one of the world’s foremost experts on innovative financing to reach the Millennium Development Goals.
In 2006, he founded, at a ministerial level, the Leading Group on Solidarity Levies to Fund Development at the Paris Conference on Innovative Development Financing Mechanisms.
He serves as Special Advisor to the «High-Level Taskforce on Innovative International Financing for Health Systems”, co-chaired by Robert Zoellick, President of the World Bank, and Gordon Brown, Prime Minister of the United Kingdom.
In 2006, he was elected President of UNITAID, a multilateral South-North organization and a global health partnership established under the auspices of the United Nations to fight AIDS, tuberculosis and malaria among the world’s most vulnerable populations. UNITAID is based at the World Health Organization Headquarters in Geneva, Switzerland.
Douste-Blazy has held several ministerial positions in his native France, including Minister of Health (1993-1995), Minister of Culture and Communication (1995-1997), Minister for Solidarity, Health and Family (2004-2005) and Minister of Foreign Affairs (2005-2007).
In 2008, he became Special Advisor to the United Nations Secretary-General on Innovative Finance for Development, with the rank of Under-Secretary-General until 2018.
Prior to embracing policy initiatives, Douste-Blazy was a practicing cardiologist and Professor of Public Health at Toulouse University in France.
From 2016 to 2017, he was visiting Professor in the Department of Global Health and Population at the Harvard Chan School of Public Health.
Chairman of UNITLIFE, UN Fund.